Modafinil vs Adderall: What the Sources Say About the Differences
In modafinil vs adderall comparisons, Drugs.com describes modafinil as "a much milder stimulant," and the Adderall label carries a high-potential abuse warning that the modafinil label does not.16 Both treat narcolepsy; their schedules, approved uses and durations differ.25
Personal account, not medical advice. Modafinil is a prescription medicine, and a Schedule IV controlled substance in the United States. Nothing here is a recommendation to start, stop or change anything. Talk to a doctor.
Modafinil vs Adderall: Side-by-Side Comparison
| Aspect | Modafinil | Adderall (mixed amphetamine salts) |
|---|---|---|
| What it is (research) | A single racemic compound, meaning a mix of two mirror-image forms; its label calls it "a wakefulness-promoting agent for oral administration," and Drugs.com notes it is "not as stimulating as Adderall" 51 | A combination tablet of four amphetamine salts: dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate 6 |
| Approved uses per the labels (research) | Its label states it is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift work disorder; GoodRx lists the same three 52 | Its label states it is indicated for ADHD and narcolepsy; GoodRx lists ADHD and narcolepsy, in adults and children 62 |
| US schedule (research) | Schedule IV controlled substance per its label 5 | Schedule II controlled substance per its label 6 |
| How sources describe its action (research) | Its label says wake-promoting actions are "similar to sympathomimetic agents including amphetamine," though the profile is not identical, and it binds the dopamine transporter without being a dopamine receptor agonist 5 | Drugs.com says it increases the concentration of dopamine and norepinephrine in the brain; American Addiction Centers describes blocking reuptake of both and releasing them from neuronal stores 13 |
| Duration (research) | An effective elimination half-life of about 15 hours after multiple doses per its label; GoodRx describes once-daily dosing as typical 52 | Label half-lives of 9.77 to 11 hours for d-amphetamine and 11.5 to 13.8 hours for l-amphetamine; GoodRx notes a shorter duration of action with possible multiple daily doses; American Addiction Centers gives about 4 to 6 hours immediate-release and about 12 hours extended-release 623 |
| Head-to-head evidence (research) | In a randomized, double-blind, placebo-controlled crossover trial, 22 adults with ADHD took both drugs: scores on the DSM-IV ADHD Checklist improved significantly over placebo with both active medications, both were "generally well tolerated," and the authors suggest modafinil "may be a viable alternative to conventional stimulants" in adults; a preliminary result in that small group 4 | Same trial (see left): the mean optimum study dose of dextroamphetamine was 21.8 mg/day against 206.8 mg/day for modafinil among the 21 completers, in a study comparing modafinil with dextroamphetamine, one component of the mixed salts 4 |
| Dependence findings (research) | Its label reports psychoactive and euphoric effects "typical of other CNS stimulants," reinforcement in monkeys trained to self-administer cocaine, and no reported withdrawal symptoms in a 14-day observation after 9 weeks of use; American Addiction Centers puts the abuse potential far below Adderall's 53 | Its boxed warning states a "high potential for abuse and misuse" leading to substance use disorder including addiction; the label also lists tolerance and withdrawal signs after abrupt discontinuation, and Drugs.com calls Adderall much more likely to cause addiction and dependence 61 |
| Cardiovascular cautions per the labels (research) | Its label reports cardiovascular reactions including chest pain and palpitations in three subjects with mitral valve prolapse or left ventricular hypertrophy, and says increased monitoring is worth considering with known cardiovascular disease 5 | Its label reports sudden death in patients with structural cardiac abnormalities or other serious cardiac disease at recommended ADHD dosages, and mean rises of about 2 to 4 mm Hg in blood pressure and 3 to 6 bpm in heart rate 6 |
What the two drugs are, and what each label approves
Drugs.com describes both as CNS stimulants with different chemical structures, and says Adderall is the brand name for a combination tablet of amphetamine and dextroamphetamine, often called mixed amphetamine salts.1 The Adderall label names those four salts in its title.6 GoodRx puts them in different classes: modafinil a wakefulness-promoting agent, Adderall a stimulant.2 American Addiction Centers, a treatment-provider page, calls modafinil a eugeroic promoting alertness and wakefulness.3
The modafinil label states the drug is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift work disorder.5 Drugs.com records FDA approval of modafinil in 1998 for narcolepsy.1 The Adderall label states it is indicated for ADHD and narcolepsy, and GoodRx lists both uses in adults and children.62 Drugs.com adds approval dates of 1996 for ADHD and 1998 for narcolepsy.1 Modafinil is not approved for ADHD; American Addiction Centers says it may be prescribed off-label for that condition, the setting the trial below tested.3
The schedules differ by two levels: modafinil a Schedule IV controlled substance per its label, Adderall Schedule II per its label, a gap Drugs.com reads as reflecting a higher propensity for abuse and dependence.561
How the sources describe each drug's action and duration
The modafinil label says its wake-promoting actions are similar to sympathomimetic agents including amphetamine, though its profile is not identical to those drugs, and it binds the dopamine transporter while not being a dopamine receptor agonist.5 Drugs.com says Adderall increases the concentration of dopamine and norepinephrine in the brain, and American Addiction Centers describes blocking their reuptake and releasing them from stores in neurons.13 On feel, Drugs.com calls modafinil "a much milder stimulant than Adderall" and "not as stimulating as Adderall."1
On length of action, the modafinil label gives an effective elimination half-life of about 15 hours after multiple doses,5 and the Adderall label gives 9.77 to 11 hours for d-amphetamine and 11.5 to 13.8 hours for the l-isomer.6 GoodRx folds the difference into its comparison: modafinil is typically taken once daily, Adderall may need multiple daily doses because of its shorter duration of action.2 American Addiction Centers puts the immediate-release form at about 4 to 6 hours and the extended-release form at about 12 hours.3
The head-to-head trial the sources point to
The direct comparison in these sources is a randomized, double-blind, placebo-controlled, three-phase crossover trial: 22 adults with ADHD took placebo, modafinil and dextroamphetamine, each phase 2 weeks.4 Dextroamphetamine is one component of the mixed-salt combination rather than Adderall itself, and the study calls its own results preliminary.4 For the 21 completers, mean optimum doses were 206.8 mg/day for modafinil and 21.8 mg/day for dextroamphetamine.4 DSM-IV ADHD Checklist scores improved significantly over placebo after both active medications, and both were generally well tolerated.4 The authors' closing line is hedged: the study "suggests that modafinil may be a viable alternative to conventional stimulants for the treatment of adults with ADHD."4
Dependence and abuse findings per the sources
The Adderall label's boxed warning states a high potential for abuse and misuse, which can lead to a substance use disorder including addiction, and its dependence section lists tolerance and withdrawal signs after abrupt discontinuation, including dysphoric mood, depression and fatigue.6 Drugs.com says Adderall is much more likely than modafinil to cause addiction and dependence and withdrawal symptoms on discontinuation.1
The modafinil label is not blank on this point: it states that modafinil produces psychoactive and euphoric effects typical of other CNS stimulants, that it is reinforcing in monkeys trained to self-administer cocaine, and that physicians should follow closely patients with a history of drug abuse.5 Its dependence section reports one placebo-controlled trial after 9 weeks of use: no reported withdrawal symptoms during 14 days of observation, though sleepiness returned in narcoleptic patients.5 American Addiction Centers, the treatment-provider page, states that modafinil's abuse potential is far lower than Adderall's, while both drugs carry abuse potential and only a few case reports identify dependence on modafinil.3 GoodRx notes that both medications carry a risk of misuse and dependence because they are controlled substances.2
Cardiovascular cautions per the labels
The modafinil label's cardiovascular section reports chest pain, palpitations, shortness of breath and transient ECG changes in three subjects with mitral valve prolapse or left ventricular hypertrophy, and says to consider increased monitoring in known cardiovascular disease.5 Drugs.com adds that modafinil can significantly increase heart rate and blood pressure.1 The Adderall label reports sudden death in patients with structural cardiac abnormalities or other serious cardiac disease treated at recommended ADHD dosages, and states that CNS stimulants raise blood pressure by a mean of about 2 to 4 mm Hg and heart rate by about 3 to 6 bpm.6 GoodRx's warnings overlap from both directions: heart problems and blood pressure and heart rate changes for modafinil, serious heart problems for Adderall.2
Common side effects the sources list
The modafinil label lists headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness and indigestion as its most common adverse reactions at 5 percent or more in the trials behind it; GoodRx's list is close, with headache at 34 percent and nausea at 11 percent.52 GoodRx lists Adderall's common side effects without numbers: upset stomach, lower appetite, weight loss, nervousness, mood changes and trouble sleeping, and its warnings add slowed growth in children; the label likewise associates CNS stimulants with weight loss and slowing of growth rate in pediatric patients.26
What the comparison comes to, per the sources
The sources line up on the skeleton: a wakefulness-promoting racemic compound approved for three sleepiness indications at Schedule IV, against a four-salt amphetamine product approved for ADHD and narcolepsy at Schedule II, a longer typical action for modafinil, a much higher abuse and dependence finding for Adderall, and cardiovascular cautions on both labels.1256 One small crossover trial in adults with ADHD found both active drugs significantly better than placebo on the ADHD checklist and both generally well tolerated.4
Related pages: modafinil vs armodafinil covers the other wakefulness-promoting pair, and modafinil as a nootropic covers the study-aid framing Drugs.com mentions.
Written by The Night Owl, a long-term user of modafinil who is not a doctor, pharmacist or healthcare provider. This page describes one person's experience alongside published research. It is not medical advice.
Sources
1: Drugs.com (drug-information Q&A page). Modafinil vs Adderall: What's the difference? n.d. https://www.drugs.com/medical-answers/modafinil-adderall-difference-3125139/
2: GoodRx Health (drug comparison page). Compare Modafinil vs. Adderall. n.d. https://www.goodrx.com/compare/modafinil-vs-adderall
3: American Addiction Centers (treatment-provider blog page). Adderall vs. Modafinil: How Do They Compare? Updated 28 May 2025. https://americanaddictioncenters.org/blog/adderall-vs-modafinil
4: Taylor FB, Russo J (peer-reviewed trial report, J Child Adolesc Psychopharmacol). Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. 2000. https://pubmed.ncbi.nlm.nih.gov/11191692/
5: DailyMed, modafinil tablets, Apotex Corp. (FDA prescription label). MODAFINIL TABLET. Label dated 21 July 2026. https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/944daf47-49a6-93ca-e348-4a0f1b6d937e.xml
6: DailyMed, Adderall tablets, Teva (FDA prescription label). ADDERALL (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE) TABLET. Label dated 17 June 2024. https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/f22635fe-821d-4cde-aa12-419f8b53db81.xml